Volume 75, Issue 3, Pages (March 2019)

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

Volume 72, Issue 1, Pages (July 2017)

Volume 70, Issue 3, Pages (September 2016)

Volume 63, Issue 3, Pages (March 2013)

Volume 68, Issue 2, Pages (August 2015)

Volume 68, Issue 6, Pages (December 2015)

Volume 70, Issue 5, Pages (November 2016)

Volume 51, Issue 2, Pages (February 2007)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 4, Pages (October 2010)

Testosterone Therapy in Men With Prostate Cancer

Global Trends in Testicular Cancer Incidence and Mortality

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 4, Pages (April 2008)

Volume 70, Issue 6, Pages (December 2016)

Volume 52, Issue 1, Pages (July 2007)

Volume 70, Issue 1, Pages (July 2016)

Volume 49, Issue 2, Pages (February 2006)

Volume 70, Issue 4, Pages (October 2016)

Volume 53, Issue 5, Pages (May 2008)

Volume 69, Issue 1, Pages (January 2016)

Volume 51, Issue 4, Pages (April 2007)

Volume 69, Issue 1, Pages (January 2016)

Volume 51, Issue 5, Pages (May 2007)

Volume 49, Issue 5, Pages (May 2006)

Prostate Cancer Epidemic in Sight?

Volume 67, Issue 2, Pages (February 2015)

Volume 68, Issue 5, Pages (November 2015)

Volume 54, Issue 4, Pages (October 2008)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 70, Issue 4, Pages (October 2016)

Prostate Cancer Detection: A View of the Future

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 67, Issue 6, Pages (June 2015)

Volume 69, Issue 3, Pages (March 2016)

Volume 71, Issue 6, Pages (June 2017)

Volume 64, Issue 6, Pages (December 2013)

Volume 73, Issue 2, Pages (February 2018)

Prostate Cancer Epidemic in Sight?

James N. Armitage, Stuart O. Irving, Neil A. Burgess European Urology

Volume 53, Issue 2, Pages (February 2008)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 68, Issue 6, Pages (December 2015)

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 4, Pages (April 2008)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 63, Issue 3, Pages (March 2013)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Volume 63, Issue 3, Pages (March 2013)

Volume 65, Issue 6, Pages (June 2014)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 50, Issue 3, Pages (September 2006)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 55, Issue 3, Pages (March 2009)

Volume 71, Issue 5, Pages (May 2017)

Testicular Cancer Variations in Time and Space in Europe

European Urology Oncology

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Volume 71, Issue 3, Pages (March 2017)

Volume 72, Issue 1, Pages (July 2017)

European Urology is “Your” Journal

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Management of Prostate Cancer: Global Strategies

Volume 51, Issue 2, Pages (February 2007)

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Presentation transcript:

Volume 75, Issue 3, Pages 515-522 (March 2019) Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer Daniel J. Canter, Julia Reid, Maria Latsis, Margaret Variano, Shams Halat, Saradha Rajamani, Kristen E. Gurtner, Zaina Sangale, Michael Brawer, Steven Stone, Stephen Bardot European Urology Volume 75, Issue 3, Pages 515-522 (March 2019) DOI: 10.1016/j.eururo.2018.10.028 Copyright © 2018 The Author(s) Terms and Conditions

Fig. 1 Cell cycle progression (CCP) score according to ancestry and Cancer of the Prostate Risk Assessment (CAPRA) score. CAPRA×interaction, p=0.035. AA=African American; Int=intermediate. European Urology 2019 75, 515-522DOI: (10.1016/j.eururo.2018.10.028) Copyright © 2018 The Author(s) Terms and Conditions

Fig. 2 (A) Progression to metastatic disease and (B) disease-specific mortality by cell cycle progression (CCP) score risk category. European Urology 2019 75, 515-522DOI: (10.1016/j.eururo.2018.10.028) Copyright © 2018 The Author(s) Terms and Conditions

Fig. 3 The 7-yr risk of metastasis by ancestry. AA=African American; CCR=clinical cell-cycle risk; HR=hazard ratio; CI=confidence interval. European Urology 2019 75, 515-522DOI: (10.1016/j.eururo.2018.10.028) Copyright © 2018 The Author(s) Terms and Conditions

Fig. 4 Clinical cell-cycle risk (CCR) score and progression to metastatic disease according to Cancer of the Prostate Risk Assessment (CAPRA) risk category. European Urology 2019 75, 515-522DOI: (10.1016/j.eururo.2018.10.028) Copyright © 2018 The Author(s) Terms and Conditions